Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | IL1B | P01584 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | KDM6A | O15550 | 1/20 | 0.33 |
| ▸ | TET3 | O43151 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM4B | O94953 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.33 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.33 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL967454 | 0.80 | L3MBTL1 (0.39) | DAOKDM4EL3MBTL1KDM6BKDM6A | |
| SCHEMBL6985131 | 0.76 | KDM4E (0.37) | KDM4EL3MBTL1KDM6BKDM6ATET3 | |
| SCHEMBL6986566 | 0.69 | L3MBTL1 (0.39) | KDM4EL3MBTL1KDM6BKDM6ATET3 | |
| SCHEMBL6987201 | 0.69 | CCR1 (0.40) | KDM4EL3MBTL1RAB9ANPC1MAPT | |
| SCHEMBL6975182 | 0.69 | L3MBTL1 (0.40) | L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL11374642 | 0.65 | KDM4E (0.41) | KDM4EL3MBTL1MEN1KMT2ABLM | |
| SCHEMBL5566400 | 0.65 | KMT2A (0.35) | KDM4EL3MBTL1MEN1RAB9AKMT2A | |
| SCHEMBL1509598 | 0.65 | LMNA (0.43) | KDM4EL3MBTL1TET2TET1EGLN1 | |
| Hydrochloric Acid SCHEMBL10655026 | 0.64 | KMT2A (0.34) | KDM4EL3MBTL1MEN1RAB9AKMT2A | |
| SCHEMBL7794481 | 0.64 | MAPT (0.51) | DAOKDM4EL3MBTL1ERN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | MATER MEDICAL RESEARCH INSTITUTE LIMITED (AU) | 2016-01-21 | — | — | US | disclosed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | disclosed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | DAO 2764/4885IL1B 4767/4885KDM4E 2921/4885 |
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | HIF1AN, CXCL12, HIF1A | DAO 4442/4885IL1B 476/4885KDM4E 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.